2007
Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor–induced peritracheal edema
Byrd JB, Shreevatsa A, Putlur P, Foretia D, McAlexander L, Sinha T, Does MD, Brown NJ. Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor–induced peritracheal edema. Journal Of Allergy And Clinical Immunology 2007, 120: 403-408. PMID: 17531305, DOI: 10.1016/j.jaci.2007.04.012.Peer-Reviewed Original ResearchConceptsACE inhibitor-associated angioedemaDPPIV-deficient ratsMagnetic resonance imagingEdema formationSubstance PSerum dipeptidyl peptidase IV activityResonance imagingCaptopril-treated ratsSaline-treated ratsReceptor-dependent mechanismDipeptidyl peptidase IV activityPeptidase IV activityACE inhibitionSerial T2F344 ratsAnimal modelsEdemaAngioedemaDPPIV activityRatsDipeptidyl peptidase activityImpaired degradationSpantideDeficiencyMagnetic resonance
2005
Regression of Existing Glomerulosclerosis by Inhibition of Aldosterone
Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of Existing Glomerulosclerosis by Inhibition of Aldosterone. Journal Of The American Society Of Nephrology 2005, 16: 3306-3314. PMID: 16192423, DOI: 10.1681/asn.2004090804.Peer-Reviewed Original ResearchConceptsInhibition of aldosteroneAngiotensin type 1 receptor antagonistType 1 receptor antagonistAdult male Sprague-DawleySeverity of glomerulosclerosisDevelopment of glomerulosclerosisMale Sprague-DawleyEffect of inhibitionCONT ratsGlomerulosclerosis indexSerum creatinineSystolic BPAntihypertensive drugsReceptor antagonistSprague-DawleySP ratsGlomerulosclerosisSpironolactoneSame ratsRatsSP groupAldosteroneFurther treatmentWkInhibition